Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies

Area of Science:

• Molecular Biology
• Immunology
• Oncology

Background:

• Alternative splicing (AS) is a key molecular mechanism influencing gene expression.
• AS is tissue-specific and dysregulated in various diseases, including cancers.
• Immuno-oncological therapies like monoclonal antibodies (mAbs) and chimeric antigen receptor (CAR) T cells show promise but have limited efficacy in many patients.

Purpose of the Study:

• To review the role of alternative splicing in cancer and its impact on immunotherapy.
• To explore the molecular mechanisms of AS and its clinical relevance.
• To discuss the potential of AS analysis for improving cancer therapy response.

Main Methods:

• Literature review of alternative splicing mechanisms and their role in cancer.
• Analysis of how splice variants affect the efficacy of immunotherapies (mAbs, CAR T cells).
• Examination of the prognostic potential of splicing factors in cancer patients.

Main Results:

• Alternative splicing generates splice variants of immunotherapeutic targets, leading to immune evasion and reduced therapy efficacy.
• Splicing patterns of targeted molecules can influence patient stratification and treatment response.
• Certain splicing factors correlate with patient outcomes, suggesting prognostic value.

Conclusions:

• Understanding alternative splicing is crucial for optimizing cancer immunotherapy.
• Analyzing splicing patterns in tumors may enable better patient selection and personalized treatment strategies.
• Further research is needed to translate AS findings into clinical applications for improved cancer patient outcomes.